Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Rangering i aksjer #15445
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Aksjekurs
$9.34
Sist synkronisert: 2026-08-31
Markedsverdi
$351.70M
Endring (1 dag)
-3.20%
Endring (1 år)
89.48%
Land
US
Handel BioAge Labs Inc. (BIOA)

Kategori

EPS for BioAge Labs Inc. (BIOA)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til BioAge Labs Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for BioAge Labs Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH